AMP-activated protein kinase activators in diabetic ulcers: from animal studies to Phase II drugs under investigation
Journal
Expert opinion on investigational drugs
Journal Volume
23
Journal Issue
9
Pages
1253
Date Issued
2014-09
Author(s)
Abstract
Diagnosed cases of diabetes have gradually increased year by year, and research on diabetes mellitus (DM) has attracted greater attention from the medical profession. Diabetic ulcers present persistent pain and the risk of bacterial infection. However, no promising treatment methods have been found. As a regulator of cellular energy balance, 5' adenosine monophosphate-activated protein kinase (AMPK) has been suggested as a drug target for DM, including such drugs as metformin.
Subjects
AMP-activated protein kinase; diabetes mellitus; diabetic ulcer; metformin; wound healing
AMP-activated protein kinase; Diabetes mellitus; Diabetic ulcer; Metformin; Wound healing
SDGs
Other Subjects
hydroxymethylglutaryl coenzyme A reductase kinase; hydroxymethylglutaryl coenzyme A reductase kinase activator; insulin; metformin; antidiabetic agent; hydroxymethylglutaryl coenzyme A reductase kinase; metformin; diabetic foot; diabetic patient; epithelization; feasibility study; human; inflammation; non insulin dependent diabetes mellitus; nonhuman; oxidative stress; phase 1 clinical trial (topic); phase 2 clinical trial (topic); review; unspecified side effect; wound healing; animal; diabetic foot; drug design; drug effects; enzymology; metabolism; molecularly targeted therapy; pathology; AMP-Activated Protein Kinases; Animals; Clinical Trials, Phase II as Topic; Diabetic Foot; Drug Design; Humans; Hypoglycemic Agents; Metformin; Molecular Targeted Therapy; Wound Healing
Publisher
INFORMA HEALTHCARE
Type
journal article